

# **Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2028**

<https://marketpublishers.com/r/C6C5F937DDBEN.html>

Date: August 2023

Pages: 175

Price: US\$ 4,950.00 (Single User License)

ID: C6C5F937DDBEN

## **Abstracts**

The global clinical trial imaging market is projected to reach USD 1.9 billion by 2028 from USD 1.3 billion in 2023, at a CAGR of 7.8% during the forecast period. The market's expansion is propelled by factors including the expansion of the pharmaceutical and biotechnology sectors, escalated research and development investments, and the proliferation of Contract Research Organizations (CROs). On the other hand, the high implementation cost of the imaging system and high cost of clinical trials are the major factors hindering the growth of this market during the forecast period.

“The service segment accounted for the highest growth rate in the clinical trial imaging market, by service & software, during the forecast period”

The clinical trial imaging market is segmented into services and software based on product. In 2022, the service segment accounted for the highest growth rate in the clinical trial imaging market. Based on type, the services segment is further classified into operational imaging services, reader analysis services, system & technical support services, and trial design consulting services. The growth of this segment is primarily attributed to the rising R&D spending, expanding clinical trials, and the demand for new disease treatment and diagnostics.

“Medical device manufacturers segment accounted for the highest CAGR”

Based on end user, the clinical trial imaging market is segmented into pharmaceutical companies, biotechnology companies, medical devices manufacturers, contract research organizations, academic and government research institutes, and other end users. In 2022, the medical device manufacturers segment accounted for the highest growth rate. This can be attributed to the increasing R&D expenditure and R&D activities by medical device manufacturers and the expanding medical devices market are the primary growth drivers of the medical device manufacturers segment.

“Asia Pacific: The fastest-growing region clinical trial imaging market”

The global clinical trial imaging market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. The surge in research and development investments and the growing inclination towards outsourcing pharmaceutical research to emerging Asian nations are the pivotal catalysts propelling the market's expansion.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).

Research Coverage:

*Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-...*

This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.

#### The report provides insights on the following pointers:

Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.

Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.

Market Development: Comprehensive information about lucrative markets – the report analyses the clinical trial imaging market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.

Competitive Assessment: In-depth assessment of market ranking, growth

strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.

## Contents

### **1 INTRODUCTION 25**

- 1.1 STUDY OBJECTIVES 25
- 1.2 MARKET DEFINITION 25
  - 1.2.1 INCLUSIONS AND EXCLUSIONS 25
  - 1.2.2 MARKETS COVERED 26
- FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION 26
  - 1.2.3 GEOGRAPHIC SCOPE 27
  - 1.2.4 YEARS CONSIDERED 27
  - 1.2.5 CURRENCY CONSIDERED 28
- 1.3 LIMITATIONS 28
- 1.4 STAKEHOLDERS 28
- 1.5 SUMMARY OF CHANGES 29
  - 1.5.1 RECESSION IMPACT 29

### **2 RESEARCH METHODOLOGY 30**

- 2.1 RESEARCH DATA 30
- 2.2 RESEARCH APPROACH 30
- FIGURE 2 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 30
  - 2.2.1 SECONDARY DATA 30
    - 2.2.1.1 Key data from secondary sources 31
  - 2.2.2 PRIMARY DATA 32
- FIGURE 3 BREAKDOWN OF INTERVIEWS: SUPPLY AND DEMAND SIDE 32
  - 2.2.2.1 Key data from primary sources 33
  - 2.2.2.2 Key industry insights 34
  - 2.2.2.3 Breakdown of primary interviews 34
- FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS 34
- FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
- 2.3 MARKET SIZE ESTIMATION 35
  - 2.3.1 BOTTOM-UP APPROACH 36
    - 2.3.1.1 Approach 1: Company revenue estimation approach 36
- FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
  - 2.3.1.2 Approach 2: Presentations of companies and primary interviews 36

2.3.1.3 Growth forecast 37

2.3.1.4 CAGR projections 37

FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37

2.3.2 TOP-DOWN APPROACH 38

FIGURE 8 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 38

2.4 MARKET BREAKDOWN & DATA TRIANGULATION 39

FIGURE 9 DATA TRIANGULATION METHODOLOGY 39

2.5 STUDY ASSUMPTIONS 40

2.6 RISK ASSESSMENT 40

2.7 LIMITATIONS 41

2.8 CLINICAL TRIAL IMAGING MARKET: RECESSION IMPACT 41

### **3 EXECUTIVE SUMMARY 43**

FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2023 VS. 2028 (USD MILLION) 43

FIGURE 11 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION) 44

FIGURE 12 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 45

FIGURE 13 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46

FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 47

### **4 PREMIUM INSIGHTS 48**

4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 48

FIGURE 15 RISING R&D SPENDING TO DRIVE MARKET GROWTH 48

4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2022 VS. 2028 48

FIGURE 16 SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028 48

4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2023 VS. 2028 49

FIGURE 17 COMPUTED TOMOGRAPHY TO COMMAND LARGEST SHARE OVER FORECAST PERIOD 49

4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028 49

FIGURE 18 ONCOLOGY TO DOMINATE MARKET, BY THERAPEUTIC AREA, TILL 2028 49

4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2023 VS. 2028 50  
FIGURE 19 PHARMACEUTICAL COMPANIES TO RETAIN MARKET LEADERSHIP  
OVER FORECAST PERIOD 50

4.6 CLINICAL TRIAL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES  
50  
FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE TILL 2028 50

## **5 MARKET OVERVIEW 51**

5.1 INTRODUCTION 51

5.2 MARKET DYNAMICS 51

FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS,  
OPPORTUNITIES, AND CHALLENGES 51

5.2.1 DRIVERS 52

5.2.1.1 Increasing R&D spending 52

5.2.1.2 Growth of pharmaceutical and biotechnology industries 52

5.2.1.3 Increasing number of CROs 52

5.2.2 RESTRAINTS 53

5.2.2.1 High implementation cost of imaging systems 53

5.2.3 OPPORTUNITIES 53

5.2.3.1 Growth opportunities in emerging economies 53

5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular  
probes, and radiopharmaceuticals 53

5.2.4 CHALLENGES 54

5.2.4.1 High cost of clinical trials 54

5.3 PRICING ANALYSIS 54

TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2022) 54

5.4 PATENT ANALYSIS 55

5.5 TRADE ANALYSIS 55

5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUSES 55

TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022  
(USD MILLION) 55

TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022  
(USD MILLION) 56

5.5.2 TRADE ANALYSIS FOR CT APPARATUSES 56

TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD  
MILLION) 56

TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD  
MILLION) 57

**5.6 VALUE CHAIN ANALYSIS 57****FIGURE 22 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS 57****5.7 SUPPLY CHAIN ANALYSIS 58****FIGURE 23 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 59****5.8 ECOSYSTEM ANALYSIS 59****FIGURE 24 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 59****TABLE 6 COMPANY ROLE IN ECOSYSTEM 60****5.9 PORTER'S FIVE FORCES ANALYSIS 61****TABLE 7 CLINICAL TRIAL IMAGING MARKET: PORTER'S FIVE FORCES ANALYSIS 61****5.9.1 THREAT OF NEW ENTRANTS 61****5.9.2 THREAT OF SUBSTITUTES 61****5.9.3 BARGAINING POWER OF BUYERS 61****5.9.4 BARGAINING POWER OF SUPPLIERS 61****5.9.5 DEGREE OF COMPETITION 61****5.10 PESTLE ANALYSIS 62****5.11 REGULATORY LANDSCAPE 62****5.11.1 NORTH AMERICA 62****5.11.1.1 US 62****5.11.1.2 CANADA 63****5.11.2 EUROPE 63****5.11.3 ASIA PACIFIC 63****5.11.3.1 Japan 63****5.11.3.2 India 63****5.11.3.3 China 64****5.11.4 LATIN AMERICA 64****5.11.4.1 Brazil 64****5.11.4.2 Mexico 64****5.11.5 MIDDLE EAST 65****5.11.6 AFRICA 65****5.12 TECHNOLOGY ANALYSIS 65****5.13 CLINICAL TRIAL IMAGING: DISRUPTIVE TECHNOLOGIES 66****FIGURE 25 REVENUE SHIFT IN CLINICAL TRIAL IMAGING MARKET 66****6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 67****6.1 INTRODUCTION 68****TABLE 8 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 68**



## 6.2 SERVICES 68

TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2021–2028  
(USD MILLION) 68

TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2021–2028  
(USD MILLION) 69

### 6.2.1 OPERATIONAL IMAGING SERVICES 69

6.2.1.1 Rising number of CROs to drive market 69

TABLE 11 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2021–2028  
(USD MILLION) 69

### 6.2.2 READ ANALYSIS SERVICES 70

6.2.2.1 Growing clinical trial activity to support growth 70

TABLE 12 READ ANALYSIS SERVICES MARKET, BY REGION, 2021–2028 (USD  
MILLION) 70

### 6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES 70

6.2.3.1 Need for continuous technical support to drive market 70

TABLE 13 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION,  
2021–2028 (USD MILLION) 71

### 6.2.4 TRIAL DESIGN & CONSULTING SERVICES 71

6.2.4.1 Rising R&D spending and need for clinical trial support to boost outsourcing  
71

TABLE 14 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION,  
2021–2028 (USD MILLION) 71

## 6.3 SOFTWARE 72

6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE TO  
BOOST ADOPTION 72

TABLE 15 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,  
2021–2028 (USD MILLION) 72

## 7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 73

### 7.1 INTRODUCTION 74

TABLE 16 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD  
MILLION) 74

### 7.2 CT 74

7.2.1 QUICK RESULTS AND LACK OF VISIBLE SIDE EFFECTS TO DRIVE  
ADOPTION 74

TABLE 17 CLINICAL TRIAL IMAGING MARKET FOR CT, BY REGION, 2021–2028 75

### 7.3 MRI 75

7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES

**TO DRIVE MARKET 75**

TABLE 18 CLINICAL TRIAL IMAGING MARKET FOR MRI, BY REGION, 2021–2028  
(USD MILLION) 76

**7.4 ULTRASOUND 76**

7.4.1 HIGH SAFETY TO ENSURE CONTINUED DEMAND 76

TABLE 19 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,  
2021–2028 (USD MILLION) 77

**7.5 PET 77**

7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC  
EVENTS TO BOOST ADOPTION 77

TABLE 20 CLINICAL TRIAL IMAGING MARKET FOR PET, BY REGION, 2021–2028  
(USD MILLION) 78

**7.6 X-RAY 78**

7.6.1 WIDE USAGE IN BONE, CHEST, AND DENTAL IMAGING TO DRIVE MARKET  
78

TABLE 21 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION, 2021–2028  
(USD MILLION) 79

**7.7 ECHOCARDIOGRAPHY 79**

7.7.1 ADVANTAGES IN DEFINING AND QUALIFYING POPULATIONS TO BOOST  
USAGE 79

TABLE 22 CLINICAL TRIAL IMAGING MARKET FOR ECHOCARDIOGRAPHY, BY  
REGION, 2021–2028 (USD MILLION) 79

**7.8 OTHER MODALITIES 80**

TABLE 23 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY  
REGION, 2021–2028 (USD MILLION) 80

**8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 81****8.1 INTRODUCTION 82**

TABLE 24 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,  
2021–2028 (USD MILLION) 82

**8.2 ONCOLOGY 82**

8.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET 82

TABLE 25 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION,  
2021–2028 (USD MILLION) 83

**8.3 INFECTIOUS DISEASES 83**

8.3.1 RISING DRUG DISCOVERY ACTIVITY TO BOOST DEMAND FOR IMAGING  
83

TABLE 26 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY

REGION, 2021–2028 (USD MILLION) 84

8.4 NEUROLOGY 84

8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE MARKET 84

TABLE 27 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 85

8.5 CVS DISORDERS 85

8.5.1 HIGH MORTALITY RATE OF CVD TO INCREASE CLINICAL TRIAL ACTIVITY 85

TABLE 28 CLINICAL TRIAL IMAGING MARKET FOR CVS DISORDERS, BY REGION, 2021–2028 (USD MILLION) 86

8.6 ENDOCRINOLOGY 86

8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET 86

TABLE 29 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 87

8.7 IMMUNOLOGICAL DISORDERS 87

8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT DEMAND FOR IMAGING IN TRIALS 87

TABLE 30 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 87

8.8 OTHER THERAPEUTIC AREAS 88

TABLE 31 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION) 88

## **9 CLINICAL TRIAL IMAGING MARKET, BY END USER 89**

9.1 INTRODUCTION 90

TABLE 32 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 90

9.2 PHARMACEUTICAL COMPANIES 90

9.2.1 PHARMA COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET 90

FIGURE 26 RISING R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION) 91

TABLE 33 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 91

9.3 BIOTECHNOLOGY COMPANIES 92

9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE MARKET 92

TABLE 34 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2020 92

TABLE 35 CLINICAL TRIAL IMAGING MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 93

9.4 MEDICAL DEVICE MANUFACTURERS 93

9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO SUPPORT GROWTH 93

TABLE 36 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2021–2028 (USD MILLION) 94

9.5 CROS 94

9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET 94  
TABLE 37 CLINICAL TRIAL IMAGING MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION) 95

9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 95

9.6.1 INCREASING RESEARCH ACTIVITY TO DRIVE MARKET 95  
TABLE 38 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 96

9.7 OTHER END USERS 96

TABLE 39 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 96

## **10 CLINICAL TRIAL IMAGING MARKET, BY REGION 97**

10.1 INTRODUCTION 98

TABLE 40 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2021–2028 (USD MILLION) 98

10.2 NORTH AMERICA 98

FIGURE 27 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 99

10.2.1 NORTH AMERICA: RECESSION IMPACT 99

TABLE 41 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100

TABLE 42 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 100

TABLE 43 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 100

TABLE 44 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 101

10.2.2 US 101

10.2.2.1 Rising biopharma investment to favor market growth 101

TABLE 45 US: PRODUCT APPROVALS IN CLINICAL TRIAL IMAGING 101

TABLE 46 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,

2021–2028 (USD MILLION) 102

TABLE 47 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 102

TABLE 48 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 103

10.2.3 CANADA 103

10.2.3.1 Rising per capita healthcare spending to drive market 103

TABLE 49 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 103

TABLE 50 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 104

TABLE 51 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 104

10.3 EUROPE 105

10.3.1 EUROPE: RECESSION IMPACT 105

TABLE 52 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106

TABLE 53 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 106

TABLE 54 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 107

TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 107

10.3.2 GERMANY 108

10.3.2.1 Germany to dominate clinical trial imaging market in Europe 108

TABLE 56 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 108

TABLE 57 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 108

TABLE 58 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 109

10.3.3 UK 109

10.3.3.1 Favorable government initiatives and growing R&D spending to drive market 109

TABLE 59 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 109

TABLE 60 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 110

TABLE 61 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028

(USD MILLION) 110

10.3.4 FRANCE 111

10.3.4.1 Presence of leading pharmaceutical companies to support growth 111

TABLE 62 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 111

TABLE 63 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 111

TABLE 64 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 112

10.3.5 ITALY 112

10.3.5.1 Increasing drug approvals to ensure sustained demand for clinical trial imaging 112

TABLE 65 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 112

TABLE 66 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 113

TABLE 67 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 113

10.3.6 SPAIN 113

10.3.6.1 Increasing biologics production to support market growth 113

TABLE 68 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 114

TABLE 69 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 114

TABLE 70 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 115

10.3.7 REST OF EUROPE 115

TABLE 71 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 115

TABLE 72 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 116

TABLE 73 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 116

10.4 ASIA PACIFIC 117

FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 117

10.4.1 ASIA PACIFIC: RECESSION IMPACT 118

TABLE 74 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118

TABLE 75 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE &



SOFTWARE, 2021–2028 (USD MILLION) 118

TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 119

TABLE 77 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 119

#### 10.4.2 CHINA 120

10.4.2.1 China to dominate APAC market throughout forecast period 120

TABLE 78 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 120

TABLE 79 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 120

TABLE 80 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 121

#### 10.4.3 JAPAN 121

10.4.3.1 Rising population and healthcare expenditure to favor market growth 121

TABLE 81 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 121

TABLE 82 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 122

TABLE 83 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 122

#### 10.4.4 INDIA 123

10.4.4.1 Rising R&D investment to boost adoption of clinical trial imaging 123

TABLE 84 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 123

TABLE 85 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 124

TABLE 86 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 124

#### 10.4.5 REST OF ASIA PACIFIC 125

TABLE 87 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 125

TABLE 88 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 125

TABLE 89 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 126

### 10.5 LATIN AMERICA 126

10.5.1 LOW COST OF RESOURCES, TAX ADVANTAGES TO ATTRACT PLAYER INTEREST 126

#### 10.5.2 LATIN AMERICA: RECESSION IMPACT 127

TABLE 90 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 127

TABLE 91 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 127

TABLE 92 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 128

#### 10.6 MIDDLE EAST & AFRICA 128

10.6.1 RISING RESEARCH FUNDING AND PARTNERSHIPS TO DRIVE MARKET 128

##### 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 129

TABLE 93 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION) 129

TABLE 94 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2021–2028 (USD MILLION) 129

TABLE 95 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 2021–2028 (USD MILLION) 130

### 11 COMPETITIVE LANDSCAPE 131

#### 11.1 OVERVIEW 131

#### 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 131

##### 11.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS 131

TABLE 96 CLINICAL TRIAL IMAGING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 131

#### 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 133

FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022) 133

#### 11.4 MARKET SHARE ANALYSIS 133

FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 133

TABLE 97 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 134

#### 11.5 COMPANY EVALUATION MATRIX (2022) 135

##### 11.5.1 STARS 135

##### 11.5.2 EMERGING LEADERS 135

##### 11.5.3 PERVASIVE PLAYERS 135

##### 11.5.4 PARTICIPANTS 135

FIGURE 31 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX, 2022 136

#### 11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 137

##### 11.6.1 PROGRESSIVE COMPANIES 137



11.6.2 STARTING BLOCKS 137

11.6.3 RESPONSIVE COMPANIES 137

11.6.4 DYNAMIC COMPANIES 137

FIGURE 32 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATIRX FOR STARTUPS/SMES, 2022 138

11.7 COMPETITIVE BENCHMARKING 138

FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF KEY PLAYERS 138

TABLE 98 COMPANY PRODUCT FOOTPRINT 139

TABLE 99 COMPANY GEOGRAPHICAL FOOTPRINT 139

11.8 COMPETITIVE SCENARIO 139

11.8.1 PRODUCT LAUNCHES & APPROVALS 139

TABLE 100 KEY PRODUCT LAUNCHES & APPROVALS (2020–2023) 139

11.8.2 DEALS 140

TABLE 101 KEY DEALS (2020–2023) 140

## **12 COMPANY PROFILES 141**

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)\*)

12.1 KEY PLAYERS 141

12.1.1 ICON PLC. 141

TABLE 102 ICON PLC.: BUSINESS OVERVIEW 141

FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2022) 142

12.1.2 BIOTELEMETRY (PHILIPS) 144

TABLE 103 BIOTELEMETRY: BUSINESS OVERVIEW 144

FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2022) 145

12.1.3 MEDPACE HOLDINGS INC. 147

TABLE 104 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 147

FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2022) 147

12.1.4 BIOMEDICAL SYSTEMS CORPORATION (ERT CLINICAL) 149

TABLE 105 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 149

12.1.5 BIOCLINICA INC. (CLARIO) 150

TABLE 106 BIOCLINICA INC.: BUSINESS OVERVIEW 150

12.1.6 IXICO PLC. 154

TABLE 107 IXICO PLC.: BUSINESS OVERVIEW 154

FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2022) 154

12.1.7 RESONANCE HEALTH ANALYSIS SERVICES (RESONANCE HEALTH) 157

TABLE 108 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW	157
FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2022)	157
12.1.8 RADIANT SAGE LLC	159
TABLE 109 RADIANT SAGE LLC: BUSINESS OVERVIEW	159
12.1.9 INTRINSIC IMAGING (WCG CLINICAL)	160
TABLE 110 WCG CLINICAL: BUSINESS OVERVIEW	160
12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES	161
TABLE 111 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW	161
12.2 OTHER PLAYERS	162
12.2.1 MEDICAL METRICS	162
12.2.2 PRISM CLINICAL IMAGING	163
12.2.3 BOSTON IMAGING CORE LAB	164
12.2.4 ANAGRAM 4 CLINICAL TRIALS	164
12.2.5 LYSCAUT MEDICAL IMAGING COMPANY	165
12.2.6 CALYX GROUP	165
12.2.7 BIOSPECTIVE	166
12.2.8 PROSCAN IMAGING	167
12.2.9 MICRON, INC.	167
12.2.10 IMAGING ENDPOINTS LI LLC.	168
12.2.11 PERSPECTUM	169
12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG GMBH	169
12.2.13 WORLDCARE CLINICAL	170
12.2.14 MEDIAN TECHNOLOGIES	170
12.2.15 INVICRO. LLC.	171

\*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)\* might not be captured in case of unlisted companies.

## **13 APPENDIX 172**

13.1 DISCUSSION GUIDE	172
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	176
13.3 CUSTOMIZATION OPTIONS	178
13.4 RELATED REPORTS	178
13.5 AUTHOR DETAILS	179

## I would like to order

Product name: Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound, ECHO), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/C6C5F937DDBEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6C5F937DDBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970